Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and efficacy of daclatasvir and simeprevir
with and without ribavirin for genotype 1 chronic hepatitis C virus infection in patients who
are treatment-naive or null responders to previous pegylated interferon/ribavirin therapy.